Latest Breaking News On - Relations advisory - Page 1 : comparemela.com

Longeveron® to Attend BIO International Convention 2024

MIAMI, May 28, 2024 (GLOBE NEWSWIRE) Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that

United statesDerek coleCompany alzheimerInvestor relations advisory solutionsLongeveron incSan diego convention centerExchange commissionAlzheimer association international conferenceInternational conventionExchange commission onInternational conferenceSan diego conventionAssociation international conferencePrivate securities litigation reform actAnnual reportQuarterly reports

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Amanda sheldonDerek coleLatha vairavanHead of corporate communicationsInvestor relations advisory solutionsExchange commissionCompensation committee of arcuti board directorsArcutis biotherapeutics incCompensation committeeArcuti boardNasdaq listing rulePrivate securities litigation reform actVice presidentRelations advisory

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024

Arcutis to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Amanda sheldonLatha vairavanDerek coleHead of corporate communicationsInvestor relations advisory solutionsArcutis biotherapeutics incReport first quarterHost conference callVice presidentRelations advisory

Longeveron Announces Pricing of $5 25 Million Public Offering

MIAMI, April 08, 2024 (GLOBE NEWSWIRE) Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as

United statesNew yorkDerek coleCompany classExchange commissionHc wainwright coExchange commission onInvestor relations advisory solutionsLongeveron or companyLongeveron incAging related frailtyLooking statementsPrivate securities litigation reform actNasdaq capital marketAnnual reportQuarterly reports

Arcutis Biotherapeutics Reports Inducement Grants Under

WESTLAKE VILLAGE, Calif., April 05, 2024 (GLOBE NEWSWIRE) Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company.

Derek coleAmanda sheldonLatha vairavanCompensation committee of arcuti board directorsArcutis biotherapeutics incInvestor relations advisory solutionsExchange commissionHead of corporate communicationsCompensation committeeArcuti boardNasdaq listing rulePrivate securities litigation reform actVice presidentRelations advisoryNasdaq arqtArcutis biotherapeutics